Glaxosmithkline Share News (GSK)

GSK sells $1 bln discounted stake in spin-off Haleon

GSK sells 240 mln Haleon shares at discount

*

Canadian court dismisses GSK Zantac litigation

(Sharecast News) - A proposed class action against GSK has been dismissed by a court in Canada, the UK drugs giant confirmed on Friday.

TOP NEWS: GSK welcomes legal ruling in Canada; sells Haleon shares

(Alliance News) - GSK PLC on Friday welcomed a legal ruling in Canada that threw out a proposed class action made on behalf of users of a heartburn drug.

GSK sells 2.4% of Haleon stake via placing for £804m

(Sharecast News) - UK pharmaceuticals company GSK said it had sold a 2.5% stake in Haleon at 335p a share, raising £804m.

LONDON BRIEFING: No Apollo offer for THG; GSK trims Haleon stake

(Alliance News) - Stocks in London were called to open higher on Friday, after data showed the UK economy expanded 0.1% over the first three months of the year.

LONDON BRIEFING: Shell sets USD4 billion buyback; Next backs outlook

(Alliance News) - Stocks in London were called to open lower on Thursday, amid a busy day for company earnings and an interest rate decision by the EU's central bank in the afternoon.

IN BRIEF: GSK receives FDA approval for Arexvy in older adults

GSK PLC - Brentford, London-based pharmaceutical firm - Announces the US Food & Drug Administration approves Arexvy, the world's first respiratory syncytial virus vaccine for older adults. States approval enables adults aged 60 years and older to be protected from RSV disease for the first time. Explains the approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease. Plans US launch before the 2023/24 RSV season.

London stocks gain ahead of Fed rate decision; Lloyds drags

Coca Cola HBC AG rises on upbeat forecast

*

LONDON MARKET CLOSE: FTSE 100 in the green ahead of Fed rate decision

(Alliance News) - Stocks in London were higher at the close on Wednesday as investor waited with bated breath for the US Federal Reserve's next interest rate decision.

Haleon is not losing ground to cheaper rivals, says CFO

LONDON, May 3 (Reuters) - Despite price increases, Haleon's roster of consumer health products have largely kept cheaper private-label competition at bay, Haleon chief financial officer Tobias Hestler said on Wednesday.

Haleon not surprised by Pfizer stake sale plans, says CFO

LONDON, May 3 (Reuters) - Pfizer's plan to sell its Haleon stake is not a surprise, the consumer health company's finance chief Tobias Hestler told Reuters on Wednesday.

Haleon Q1 profit misses analyst expectations

LONDON, May 3 (Reuters) - Haleon, the world's biggest standalone consumer health business, on Wednesday reported first-quarter profit below analyst expectations.

US FDA panel backs restricted use of AstraZeneca's prostate cancer drug

April 28 (Reuters) - A panel of U.S. Food and Drug Administration advisers on Friday voted for the restricted use of British drugmaker AztraZeneca Plc's experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.

GSK gets positive EU opinion for respiratory syncytial virus vaccine

(Alliance News) - GSK PLC on Thursday said its respiratory syncytial virus vaccine candidate has gained positive opinion from the European Medicines Agency body.

IN BRIEF: Schroders taps PwC exec as CFO, GSK CFO as non-exec director

Schroders PLC - London-based investment manager - Hires Richard Oldfield to succeed Richard Keers as chief financial officer and an executive director. Oldfield currently is vice chair & global markets leader at accountants PricewaterhouseCoopers. Oldfield will join Schroders on October 2, and Keers will depart on December 31 after 10 years with the company. At Schroders, Oldfield will be responsible for "firm-wide operations" and for "financial management, risk management, technology, capital and treasury".